The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. According to official data, there have been ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

The current number of long COVID-19 cases may already be costing the U.S. $2.01–6.56 billion dollars per year, according to a ...

Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA ...

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...